Innovator IBD 50 ETF Rating $36.53 +0.62 (+1.73%) As of 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Innovator IBD 50 ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FFTY Aggregate RatingModerate Buy 2.67Holdings in FFTY have an aggregate rating of Moderate Buy based on 386 analyst ratings issued in the past year covering 25 companies (75.4% of the portfolio).FFTY Aggregate Price Target$36.53High Prediction$36.53Average Prediction$36.53Low Prediction$36.53Holdings in FFTY have an aggregate price target of $36.53 and a range of $36.53 to $36.53 covering 25 companies (75.4% of the portfolio).FFTY Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy19 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Innovator IBD 50 ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 FFTY Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings3.81%HNGEHinge Health$91.03-0.9%3.3725 of 5 stars2.83$100.57 10.5%183.71%TERTeradyne$338.59-0.9%4.9358 of 5 stars2.81$396.80 17.2%16Trending NewsGap Down3.62%WTWisdomTree$24.80+4.5%2.799 of 5 stars2.57$23.66 -4.6%7Positive NewsGap Up3.60%OSCROscar Health$32.07+5.7%4.2217 of 5 stars2.42$26.22 -18.2%12Insider Trade3.52%OUSTOuster$35.83+2.9%3.0105 of 5 stars2.56$54.67 52.6%93.51%KNSAKiniksa Pharmaceuticals International$80.47+0.7%3.5855 of 5 stars2.80$87.38 8.6%10News CoveragePositive NewsInsider Trade3.50%ENVAEnova International$233.56+2.9%3.5477 of 5 stars3.11$247.83 6.1%93.41%NTRANatera$327.67+0.8%2.5118 of 5 stars2.82$319.38 -2.5%22Positive News3.34%GKOSGlaukos$179.94+0.2%1.6374 of 5 stars2.79$178.08 -1.0%14Positive News3.30%ZETAZeta Global$32.56+7.0%2.8814 of 5 stars2.64$30.77 -5.5%143.27%CARECarter Bankshares$31.77+0.5%2.6054 of 5 stars2.20$30.75 -3.2%5Positive News3.18%ECOOkeanis Eco Tankers$69.68+1.0%2.0877 of 5 stars2.67$59.52 -14.6%6Gap Down3.12%SNSharkNinja$174.65-0.3%4.3215 of 5 stars2.92$188.59 8.0%133.10%EXPEExpedia Group$303.14-1.6%4.7895 of 5 stars2.45$318.71 5.1%40Analyst Upgrade3.08%XMTRXometry$93.04+0.9%2.4123 of 5 stars2.58$108.33 16.4%12Insider Trade2.93%HWMHowmet Aerospace$260.50+3.0%4.5413 of 5 stars2.95$316.22 21.4%20Positive NewsAnalyst ForecastOptions Volume2.85%LQDALiquidia$68.63-1.5%4.2953 of 5 stars2.45$98.08 42.9%11Trending News2.73%DAVEDave$390.86+4.8%3.1883 of 5 stars2.80$410.82 5.1%152.69%EXELExelixis$59.13+1.0%2.9024 of 5 stars2.35$50.07 -15.3%20Analyst Upgrade2.38%VCTRVictory Capital$113.46+1.9%4.2158 of 5 stars2.63$105.71 -6.8%82.27%NETCloudflare$284.44+4.3%4.281 of 5 stars2.58$320.19 12.6%33Analyst ForecastGap Up2.25%SEZLSezzle$122.96+1.2%4.2244 of 5 stars2.67$146.50 19.1%92.14%SNOWSnowflake$356.78+16.7%3.0169 of 5 stars2.83$405.92 13.8%40Trending NewsEarnings ReportAnalyst ForecastGap UpHigh Trading Volume2.04%STTState Street$193.91+2.0%4.7761 of 5 stars2.81$185.38 -4.4%16Positive News2.00%ADPTAdaptive Biotechnologies$24.57-0.4%1.6853 of 5 stars2.57$24.42 -0.6%7Positive NewsGap Up This page (NYSEARCA:FFTY) was last updated on 9/3/2026 by MarketBeat.com Staff. From Our PartnersThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovator IBD 50 ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovator IBD 50 ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
